# A stochastic individual-based model to explore the role of spatial interactions and antigen recognition in the immune response against solid tumours

## TL;DR

This paper introduces a spatial stochastic individual-based model that captures antigen recognition and spatial interactions between immune and cancer cells, providing insights into immune response dynamics against solid tumours.

## Contribution

It presents a novel model integrating antigen expression, recognition, and spatial movement of immune cells, advancing understanding of tumour-immune interactions.

## Key findings

- Conditions for tumour clearance, dormancy, or escape identified
- Antigen heterogeneity impacts immune efficacy
- Spatial interactions influence immune response outcomes

## Abstract

Spatial interactions between cancer and immune cells, as well as the recognition of tumour antigens by cells of the immune system, play a key role in the immune response against solid tumours. The existing mathematical models generally focus only on one of these key aspects. We present here a spatial stochastic individual-based model that explicitly captures antigen expression and recognition. In our model, each cancer cell is characterised by an antigen profile which can change over time due to either epimutations or mutations. The immune response against the cancer cells is initiated by the dendritic cells that recognise the tumour antigens and present them to the cytotoxic T cells. Consequently, T cells become activated against the tumour cells expressing such antigens. Moreover, the differences in movement between inactive and active immune cells are explicitly taken into account by the model. Computational simulations of our model clarify the conditions for the emergence of tumour clearance, dormancy or escape, and allow us to assess the impact of antigenic heterogeneity of cancer cells on the efficacy of immune action. Ultimately, our results highlight the complex interplay between spatial interactions and adaptive mechanisms that underpins the immune response against solid tumours, and suggest how this may be exploited to further develop cancer immunotherapies.